ERBB2 and breast cancer: This paper addresses the status of hormone receptors (HR+ versus HR-) to study the prognosis of two types of HER2-positive breast cancers, which are highly aggressive and have a high recurrence rate and high risk of metastasis, accounting for approximately 20%-30% of all breast cancers (14).